Months after changing hands in a $128 million deal, CRO Synexus is gearing up for growth, looking to expand its geographic reach and areas of expertise.
In February, private equity outfit LDC bought Synexus from Lyceum Capital, and now the company is recruiting new board members and tasking them with accelerating the CRO's growth.
Stepping in as chairman is Charles Woler, formerly head of French operations for Roche ($RHHBY) and the European business of SmithKline Beecham. Joining him is Hywel Evans, a veteran of Quintiles ($Q); Benjamin Harrild of BlueBay Asset Management; and LDC's Ged Gould and Simon Braham.
The plan now is to hit the gas on growth, both organic and through acquisition, CEO Christophe Berthoux said.
"We are confident they will help us deliver the ambitious plans we have to expand not only geographically with new research centers but also in broadening the number of therapy areas we offer to our pharma and CRO clients," Berthoux said in a statement.
Synexus specializes in handling patient recruitment for sponsors and other CROs, with a list of clients that includes GlaxoSmithKline ($GSK) and Pfizer ($PFE). Over the past few years, the company has inked buyout deals around the world to get its hands on new recruitment centers.
- read the statement